Nat Lester-Coll, Chair of the Department of Radiation Oncology at The University of Vermont Health Network, shared a post X:
“ESTRO26, Ane Appelt.
APHRODITE trial: EDRT (62Gy SIB) boosted 6-mo cCR to 49.4% vs 33.3% with SDRT in early rectal cancer (+16%; OR 2.27, p=0.038). First RCT evidence for dose escalation benefit + low toxicity!”
Other articles featuring Nat Lester-Coll on OncoDaily.
